Follow
Joseph S Bertino Jr
Joseph S Bertino Jr
Bertino Consulting
Verified email at ix.netcom.com - Homepage
Title
Cited by
Cited by
Year
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes
DS Streetman, JS Bertino Jr, AN Nafziger
Pharmacogenetics and Genomics 10 (3), 187-216, 2000
5762000
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria
ADM Kashuba, AN Nafziger, GL Drusano, JS Bertino Jr
Antimicrobial agents and chemotherapy 43 (3), 623-629, 1999
4921999
The safety profile of the fluoroquinolones
J Bertino Jr, D Fish
Clinical therapeutics 22 (7), 798-817, 2000
3322000
Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450–metabolized drugs
JF Rogers, AN Nafziger, JS Bertino Jr
The American journal of medicine 113 (9), 746-750, 2002
3172002
Back to the future: using aminoglycosides again and how to dose them optimally
GM Eliopoulos, GL Drusano, PG Ambrose, SM Bhavnani, JS Bertino, ...
Clinical infectious diseases 45 (6), 753-760, 2007
3132007
The absolute bioavailability of oral melatonin
RL DeMuro, AN Nafziger, DE Blask, AM Menhinick, JS Bertino Jr
The Journal of Clinical Pharmacology 40 (7), 781-784, 2000
2912000
Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring
JS Bertino Jr, LA Booker, PA Franck, PL Jenkins, KR Franck, AN Nafziger
Journal of Infectious Diseases 167 (1), 173-179, 1993
2511993
Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics
JS Bertino Jr
Clinical Ophthalmology, 507-521, 2009
2412009
Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N‐acetyltransferase‐2, and xanthine oxidase activities with the …
S Chainuvati, AN Nafziger, JS Leeder, A Gaedigk, GL Kearns, E Sellers, ...
Clinical pharmacology & therapeutics 74 (5), 437-447, 2003
1992003
Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N‐acetyltransferase‐2, and xanthine oxidase with the “Cooperstown cocktail”
DS Streetman, JF Bleakley, JS Kim, AN Nafziger, JS Leeder, A Gaedigk, ...
Clinical Pharmacology & Therapeutics 68 (4), 375-383, 2000
1862000
Methicillin-resistant Staphylococcus aureus outbreak: a consensus panel's definition and management guidelines
RP Wenzel, DR Reagan, JS Bertino Jr, EJ Baron, K Arias
American journal of infection control 26 (2), 102-110, 1998
1541998
Aminoglycoside dosing weight correction factors for patients of various body sizes
AM Traynor, AN Nafziger, JS Bertino Jr
Antimicrobial agents and chemotherapy 39 (2), 545-548, 1995
1461995
Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults
M Chen, AN Nafziger, GL Drusano, L Ma, JS Bertino Jr
Antimicrobial agents and chemotherapy 50 (4), 1222-1227, 2006
1392006
Cost burden of viral respiratory infections: issues for formulary decision makers
JS Bertino
Disease-a-Month 49 (3), 225-239, 2003
1392003
Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients
LA Keyser, M Karl, AN Nafziger, JS Bertino
Archives of internal medicine 160 (10), 1485-1488, 2000
1382000
Individualized pharmacokinetic monitoring results in less aminoglycoside‐associated nephrotoxicity and fewer associated costs
DS Streetman, AN Nafziger, CJ Destache, JS Bertino Jr
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 21 (4 …, 2001
1332001
Comparison of midazolam and simvastatin as cytochrome P450 3A probes
E Chung, AN Nafziger, DJ Kazierad, JS Bertino Jr
Clinical pharmacology & therapeutics 79 (4), 350-361, 2006
1312006
Quantification of 3‐month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam
ADM Kashuba, JS Bertino Jr, ML Rocci Jr, RW Kulawy, DJ Beck, ...
Clinical Pharmacology & Therapeutics 64 (3), 269-277, 1998
1271998
Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing
DJ Demczar, AN Nafziger, JS Bertino Jr
Antimicrobial agents and chemotherapy 41 (5), 1115-1119, 1997
1241997
Quantitation of three‐month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N‐acetyltransferase‐2, and xanthine oxidase …
ADM Kashuba, JS Bertino Jr, GL Kearns, JS Leeder, AW James, ...
Clinical Pharmacology & Therapeutics 63 (5), 540-551, 1998
1161998
The system can't perform the operation now. Try again later.
Articles 1–20